Pyramid Biosciences, Inc

Medisyn Technologies, Inc.

Boston University

Mitotix, Inc.

Gpc Biotech, Inc.

Satori Pharmaceuticals, Inc.

Kollol Pal

Stephane Ciblat

Vincent Albert

Nicolas Bruneau-Latour

Jonathan Boudreault

Javier Llompart

Jorge Galvez

Arthur F Kluge

James Joseph Collins

Jon H Come

Muzammil M Mansuri

Frank Clemens Schroeder

Krishna K Murthi

Michael Thormann

Mark Arthur Findeis

Andreas Treml

Vivian Berlin

Michael Almstetter

Daniel J Dwyer

Gustave Bergnes

Michael Kohanski

Jamey Wierzbowski

Guillaume Cottarel

The application relates to pyrazolo[1,5-a]pyrimidine derivatives of formula (IV) as Trk kinase inhibitors for treating cancer and inflammatory diseases.

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1H-pyrazol-1-yl)pyrazolo [1,5-A]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

The application relates to inhibitors of Trk kinases useful in the treatment of Trk kinase associated diseases and disorders, having the Formula: wherein A, L, X, X, and Y are described herein.

5-(2,5-difluorophenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazolo[1,5-a]pyrimidine derivatives and related compounds as Trk kinase inhibitors for treating cancer

The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition.

RecA inhibitors with antibiotic activity, compositions and methods of use

Compositions and uses associated with the MT477 family of compounds are disclosed. Particular structural features and properties of the compounds are described in detail. Uses include administering an MT477 family member to a patient for therapeutic purposes. Compositions include chemicals belonging to the MT477 family and pharmaceuticals that contain such chemicals.

Therapeutic compound and treatments

As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disorders wherein said method comprises administering to a patient a compound of the present invention, or composition thereof. Said method is useful for treating or lessening the severity of, for example, Alzheimer's disease.

Compounds useful for treating neurodegenerative disorders

The present invention relates to compositions and methods for inhibiting fungal growth. In particular, the present invention relates to methods for use as anti-fungal agents of inhibitors, and compositions thereof, of fungal GGPTase. The inhibitors of fungal GGPTase may be peptides, peptidomimetics, or non-peptides.

Compositions and methods for inhibiting fungal growth

The invention provides novel inhibitors of cyclin-dependent kinases, in particular inhibitors of the CDK/cyclin complexes such as CDK4/cyclin D1. The novel compounds are analogs of chromones. These compounds can be used for inhibiting excessive or abnormal cell proliferation. Thus, the novel compounds are useful for treating a subject with a disorder associated with excessive cell proliferation, such as cancer.

Inhibitors of cyclin dependent kinases

Growing community of inventors

Needham, MA, United States of America

Kollol Pal